Literature DB >> 18195120

Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.

T A Gaziano1.   

Abstract

Cardiovascular disease is the leading cause of death in those over the age of 45 in Africa. The economic toll from cardiovascular diseases is equally devastating, leading to billions of dollars lost due to healthcare costs and reduced productivity from the disabling and fatal outcomes related to diabetes, hypertension, stroke, valvular heart disease, and heart failure. Much of it is preventable. With reasonable screening programmes and judicious use of scarce resources much of the suffering can be alleviated. This article reviews the economic burden attributable to cardiovascular disease in Africa and many of the potential cost-effective solutions to the large burden. It further outlines many of the areas where we know less and must focus our future research in trying to outline cost-effective solutions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18195120     DOI: 10.1136/hrt.2007.128785

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  35 in total

1.  The economic burden of atherothrombosis in Greece: results from the THESIS study.

Authors:  Nikos Maniadakis; Georgia Kourlaba; Dennis V Cokkinos; Aggeliki Angeli; John Kyriopoulos
Journal:  Eur J Health Econ       Date:  2012-07-10

2.  Disease Prevention: The moving target of global cardiovascular health.

Authors:  Rajesh Vedanthan; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2009-05       Impact factor: 32.419

Review 3.  The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy.

Authors:  Lijun Qian; Barsha Thapa; Jian Hong; Yanmei Zhang; Menglin Zhu; Ming Chu; Jing Yao; Di Xu
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

4.  Economic cost of primary prevention of cardiovascular diseases in Tanzania.

Authors:  Frida Ngalesoni; George Ruhago; Ole F Norheim; Bjarne Robberstad
Journal:  Health Policy Plan       Date:  2014-08-11       Impact factor: 3.344

5.  Bridging Income Generation with Group Integrated Care for cardiovascular risk reduction: Rationale and design of the BIGPIC study.

Authors:  Rajesh Vedanthan; Jemima H Kamano; Hana Lee; Benjamin Andama; Gerald S Bloomfield; Allison K DeLong; David Edelman; Eric A Finkelstein; Joseph W Hogan; Carol R Horowitz; Simon Manyara; Diana Menya; Violet Naanyu; Sonak D Pastakia; Thomas W Valente; Cleophas C Wanyonyi; Valentin Fuster
Journal:  Am Heart J       Date:  2017-03-23       Impact factor: 4.749

6.  Lack of focus on cardiovascular disease in sub-Saharan Africa.

Authors:  Ana Olga Mocumbi
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

7.  Combined effects of hypertension and heart rate on the risk of stroke and coronary heart disease: a population-based prospective cohort study among Inner Mongolians in China.

Authors:  Chongke Zhong; Xiaoyan Zhong; Tian Xu; Hao Peng; Hongmei Li; Mingzhi Zhang; Aili Wang; Tan Xu; Yingxian Sun; Yonghong Zhang
Journal:  Hypertens Res       Date:  2015-08-20       Impact factor: 3.872

8.  Effect of morin, a flavonoid against DOCA-salt hypertensive rats: a dose dependent study.

Authors:  P Prahalathan; S Kumar; B Raja
Journal:  Asian Pac J Trop Biomed       Date:  2012-06

9.  The effect of ozone on blood pressure in DOCA-salt-induced hypertensive rats.

Authors:  Raziye Akcılar; Sezer Akçer; Hasan Şimşek; Aydın Akcılar; Zeynep Bayat; Osman Genç
Journal:  Int J Clin Exp Med       Date:  2015-08-15

10.  PASCAR and WHF Cardiovascular Diseases Scorecard project.

Authors:  Mpiko Ntsekhe; Jean M Fourie; Wihan Scholtz; Oana Scarlatescu; George Nel; Karen Sliwa
Journal:  Cardiovasc J Afr       Date:  2021 Jan-Feb       Impact factor: 1.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.